Cargando…

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy

Molecularly targeted cancer therapies substantially improve patient outcomes, although the durability of their effectiveness can be limited. Resistance to these therapies is often related to adaptive changes in the target oncoprotein which reduce binding affinity. The arsenal of targeted cancer ther...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kelm, Jeremy M., Pandey, Deepti S., Malin, Evan, Kansou, Hussein, Arora, Sahil, Kumar, Raj, Gavande, Navnath S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061819/ https://www.ncbi.nlm.nih.gov/pubmed/36991452 http://dx.doi.org/10.1186/s12943-022-01707-5

Ejemplares similares

ING Proteins: Tumour Suppressors or Oncoproteins
por: Jacquet, Karine, et al.
Publicado: (2021)

Recent Advances in the Development of Non-PIKKs Targeting Small Molecule Inhibitors of DNA Double-Strand Break Repair
por: Kelm, Jeremy M., et al.
Publicado: (2022)

Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers
por: Liu, Li, et al.
Publicado: (2022)

Targeting Protein Kinases Degradation by PROTACs
por: Yu, Fei, et al.
Publicado: (2021)

DeepPROTACs is a deep learning-based targeted degradation predictor for PROTACs
por: Li, Fenglei, et al.
Publicado: (2022)

PROTAC targeted protein degraders: the past is prologue
por: Békés, Miklós, et al.
Publicado: (2022)

Mutant-selective degradation by BRAF-targeting PROTACs
por: Alabi, Shanique, et al.
Publicado: (2021)

Light-mediated multi-target protein degradation using arylazopyrazole photoswitchable PROTACs (AP-PROTACs)
por: Zhang, Qisi, et al.
Publicado: (2022)

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy
por: Qi, Si-Min, et al.
Publicado: (2021)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Synthesis and Biological Evaluation of Cardiac Glycosides for Cancer Therapy by Targeting the DNA Damage Response
por: Ainembabazi, Diana, et al.
Publicado: (2022)

Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
por: Ma, Sinan, et al.
Publicado: (2022)

BacPROTACs mediate targeted protein degradation in bacteria
por: Morreale, Francesca E., et al.
Publicado: (2022)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein
por: McClurg, Urszula L, et al.
Publicado: (2018)

Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy()
por: Ray, Dipankar, et al.
Publicado: (2015)

Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
por: Gabizon, Ronen, et al.
Publicado: (2020)

Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
por: Naito, Mikihiko, et al.
Publicado: (2019)

Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
por: Alabi, Shanique B., et al.
Publicado: (2021)

Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy
por: Yuan, Minghua, et al.
Publicado: (2021)

Degradation of proteins by PROTACs and other strategies
por: Wang, Yang, et al.
Publicado: (2020)

PROTAC-Based Protein Degradation as a Promising Strategy for Targeted Therapy in Sarcomas
por: Mancarella, Caterina, et al.
Publicado: (2023)

A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer
por: Ma, Danhui, et al.
Publicado: (2020)

Correction to Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
por: Gabizon, Ronen, et al.
Publicado: (2020)

PROTACs: Emerging Targeted Protein Degradation Approaches for Advanced Druggable Strategies
por: Sincere, Nuwayo Ishimwe, et al.
Publicado: (2023)

Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
por: Wang, Huifang, et al.
Publicado: (2023)

Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
por: Gasic, Ivana, et al.
Publicado: (2020)

RNA‐PROTACs: Degraders of RNA‐Binding Proteins
por: Ghidini, Alice, et al.
Publicado: (2020)

Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
por: Kim, Hanbyeol, et al.
Publicado: (2022)

Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader
por: Tovell, Hannah, et al.
Publicado: (2019)

Implications of the USP10-HDAC6 axis in lung cancer - A path to precision medicine
por: Zhang, Xiaohong Mary, et al.
Publicado: (2016)

Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
por: Ishikawa, Minoru, et al.
Publicado: (2020)

Targeted Degradation of Oncogenic KRAS(G12C) by VHL-Recruiting PROTACs
por: Bond, Michael J., et al.
Publicado: (2020)

Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation
por: Ruffilli, Camilla, et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Degrading AR-Dependent Cancers: Expanding the Role of PROTACs
por: Michmerhuizen, Anna R., et al.
Publicado: (2020)

Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
por: Liu, Jing, et al.
Publicado: (2021)

Recent Advances of Degradation Technologies Based on PROTAC Mechanism
por: Xiao, Mingchao, et al.
Publicado: (2022)

Natural Products as an Emerging Therapeutic Alternative in the Treatment of Neurological Disorders
por: Karim, Nasiara, et al.
Publicado: (2018)

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pdsjkgea70ptsc98piadm9e6gr